Search

Veracyte Inc

Aperta

SettoreSettore sanitario

41.21 -3.04

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

40.98

Massimo

43.6

Metriche Chiave

By Trading Economics

Entrata

-3.2M

25M

Vendite

11M

150M

P/E

Media del settore

33.774

57.002

EPS

0.37

Margine di Profitto

16.957

Dipendenti

755

EBITDA

-11M

24M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+35.56% upside

Dividendi

By Acuity

Utili prossimi

3 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-718M

3.7B

Apertura precedente

44.25

Chiusura precedente

41.21

Notizie sul Sentiment di mercato

By Acuity

50%

50%

171 / 340 Classifica in Healthcare

Veracyte Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 ago 2026, 19:51 UTC

Veracyte Inc shares are lower today, breaking a trend of higher closes. No specific news was identified for this decline amid notable market volume.

12 ago 2026, 20:01 UTC

Veracyte Inc shares are lower today, following a broader market decline. The stock remains significantly below its 20-day moving average.

11 ago 2026, 19:26 UTC

News

Veracyte Inc reported second-quarter revenue of $150.32 million and raised its 2026 outlook to $590 million to $596 million, boosting shares higher.

10 ago 2026, 19:36 UTC

News

Veracyte Inc shares declined Monday, trading lower since Friday's close amid broader market volatility and rising oil prices affecting inflation expectations.

7 ago 2026, 19:26 UTC

Correlated Moves

Veracyte Inc shares are higher, supported by a rise in the ARK Genomic Revolution ETF and broader small-cap strength from the Russell 2000 Index.

6 ago 2026, 19:26 UTC

Veracyte Inc shares are higher today, despite earlier losses. No specific news was identified to explain the price movement during the session.

5 ago 2026, 19:32 UTC

Veracyte Inc's shares are lower, reflecting broader market sentiment amid recent crude oil price declines. Trading volume is unusually high today.

4 ago 2026, 19:36 UTC

News
Correlated Moves

Veracyte shares are rising as Piper Sandler and Stephens maintain Overweight ratings, despite lowering price targets to $54 and $55, respectively.

3 ago 2026, 20:06 UTC

Veracyte Inc's shares are lower today, diverging from broader market gains amid high trading volume. No specific news was identified to explain the decline.

1 ago 2026, 00:01 UTC

Veracyte Inc is trading lower in after-market hours, reflecting broader market declines. Shares remain near the lower end of their one-month range.

31 lug 2026, 20:02 UTC

News
Social Media

Veracyte Inc shares are lower despite positive analyst outlooks and target increases from Freedom and Needham following a recent earnings report that exceeded expectations.

30 lug 2026, 23:21 UTC

News
Social Media

Veracyte shares fell in after-market trading despite reporting second-quarter revenue of $150.3 million and adjusted EPS of $0.54, exceeding expectations.

29 lug 2026, 19:47 UTC

Macro Event

Veracyte Inc's shares are advancing as the Federal Reserve maintains interest rates. The decision aligns with market expectations amid ongoing economic expansion.

28 lug 2026, 15:22 UTC

Veracyte Inc. shares are higher today, supported by broader strength in biotechnology stocks. No specific news was identified to explain the price movement.

27 lug 2026, 20:14 UTC

Veracyte Inc shares are higher in after-market trading, despite no specific news. Broader market sentiment may be affected by declining crude oil prices.

24 lug 2026, 22:16 UTC

Correlated Moves

Veracyte Inc shares declined during after-market hours, reflecting broader weakness in the biotechnology sector. The stock shifted toward the lower end of its one-month trading range.

22 lug 2026, 20:13 UTC

Correlated Moves

Veracyte Inc shares are lower in after-market trading, reflecting broader market declines amid rising crude oil prices and geopolitical tensions.

21 lug 2026, 17:16 UTC

Correlated Moves

Veracyte Inc shares are higher today, recovering after three days of declines. The stock is now above its 20-day moving average.

20 lug 2026, 20:01 UTC

Correlated Moves

Veracyte Inc shares declined sharply today, marking three consecutive lower sessions amid broader market weakness and heightened volatility related to geopolitical tensions.

Confronto tra pari

Modifica del prezzo

Veracyte Inc Previsione

Obiettivo di Prezzo

By TipRanks

35.56% in crescita

Previsioni per 12 mesi

Media 57.75 USD  35.56%

Alto 70 USD

Basso 44 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Veracyte Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

10 ratings

8

Acquista

1

Mantieni

1

Vendi

Sentiment

By Acuity

171 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
help-icon Live chat